Tuesday, 23 June 2026European Markets

#Novo Nordisk

8 articles

Novo Nordisk Closes Cell Therapy Unit, Outsources Parkinson's to AI-Native Partner

European Pharma

Novo Nordisk Closes Cell Therapy Unit, Outsources Parkinson's to AI-Native Partner

Salvado•Jun 19, 2026

Novo Nordisk Outsources Parkinson's Programs to AI Partner as Stock Surges 24.9%

European Pharma

Novo Nordisk Outsources Parkinson's Programs to AI Partner as Stock Surges 24.9%

Salvado•Jun 9, 2026

Novo Nordisk Licenses Parkinson's Therapy to AI Startup, Shares Rise 24.9% in 30 Days

European Pharmaceutical Innovation

Novo Nordisk Licenses Parkinson's Therapy to AI Startup, Shares Rise 24.9% in 30 Days

Salvado•Jun 5, 2026

Novo Nordisk's 24.9% Rally Backs AI Partnership Model Over In-House Biology

European Pharma

Novo Nordisk's 24.9% Rally Backs AI Partnership Model Over In-House Biology

Salvado•May 31, 2026

Novo Nordisk Stock Surges 24.9% in 30 Days as AI Reshapes European Drug Discovery

European Pharma

Novo Nordisk Stock Surges 24.9% in 30 Days as AI Reshapes European Drug Discovery

Salvado•May 27, 2026

Novo Nordisk Closes Cell Therapy Unit, Outsources Parkinson's to AI Partner as Stock Surges 25%

European Pharmaceutical Innovation

Novo Nordisk Closes Cell Therapy Unit, Outsources Parkinson's to AI Partner as Stock Surges 25%

Salvado•May 18, 2026

Novo Nordisk Licenses Parkinson's Cell Therapy to AI Partner, Closes Internal Unit

European Pharma

Novo Nordisk Licenses Parkinson's Cell Therapy to AI Partner, Closes Internal Unit

Salvado•May 16, 2026

Novo Nordisk Stock Jumps 24.9% After Closing Cell Therapy Unit and Licensing Parkinson's Program to AI Partner

European Pharma

Novo Nordisk Stock Jumps 24.9% After Closing Cell Therapy Unit and Licensing Parkinson's Program to AI Partner

Salvado•May 13, 2026